ADARx Pharmaceuticals is the lead sponsor of 9 current clinical trials in our UK, USA, China and EU (CTIS) registers. 7 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are ADX-324, Dopamine and Telitacicept. The most-studied condition is Hereditary Angioedema - Type 1.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499 · Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
Drug: ADX-324 |
Phase 3 | Recruiting | 2026-04 | UK, USA, China |
|
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213 · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1
Drug: ADX-324 |
Phase 3 | Recruiting | 2025-08 | UK, USA, China |
|
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269 · ClinicalTrials.gov ↗ · Geographic Atrophy Secondary to Age-related Macular Degeneration
|
Phase 2 | Recruiting | 2025-11 | UK, USA |
|
Phase 1 Study of ADX-626 in Healthy Participants
NCT07081503 · ClinicalTrials.gov ↗ · Healthy Adult Participants
|
Phase 1 | Recruiting | 2025-08 | UK |
|
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
NCT05876312 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 1/2 | Recruiting | 2023-08 | UK |
|
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359 · ClinicalTrials.gov ↗ · IgAN, C3G, Complement-mediated Kidney Disease
|
Phase 2 | Recruiting | 2025-08 | UK, USA |
|
Chinese Adults With Kidney Disease
NCT07522099 · ClinicalTrials.gov ↗ · Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN
Drug: Telitacicept |
Phase 2 | Recruiting | 2026-05 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with ADARx Pharmaceuticals as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
2025-521353-16-00 · CTIS ↗ · Immune System Diseases
|
Phase 3 | Ongoing | Poland, Italy, Hungary + 8 more |
|
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
2025-521779-30-00 · CTIS ↗ · Eye Diseases
|
Phase 2 | Authorised | Germany, Portugal, Italy + 1 more |
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 6 | 6 |
| Clinical trials in USA | 4 | 4 |
| Clinical trials in China | 3 | 3 |
| EU register (CTIS) | 2 | — |
A trial with sites in more than one country appears in each of those registers.
ADARx Pharmaceuticals is the lead sponsor of 7 current trials on ClinicalTrials.gov in our UK, USA and China registers, and 2 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 7 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 3 drugs and biologicals as interventions. The most frequent are ADX-324 (3), Dopamine (1) and Telitacicept (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.